Medical Costs of Adults With COVID-19 in Dominican Republic **During the Endemic Phase: A Micro-Costing Study**

Vásquez E¹, Lasalvia P¹, <u>Baldi-Castro JJ²</u>, Barrantes-Aragón LA², Villafranca A², Marcano-Lozada M², Ochapa M³, Mendoza CF⁴,

Rojas-Fermín R⁵, Rodríguez-Taveras CJ⁶

¹NeuroEconomix, Bogotá, Colombia; ²Pfizer Central America and the Caribbean, Escazú, Costa Rica; ³Morgan State University School of Community Health and Policy, Pfizer Inc., MD, USA; ⁴Pfizer Inc., CDMX, Mexico; ⁵Hospital General Plaza de la Salud, Santo Dominican Republic; ⁶Hospital Unidad de Aislamiento del Centro de Obstetricia y Ginecología (UACOG), Santo Domingo, Dominican Republic

INTRODUCTION

- As of October 20th, 2024, the WHO has reported around 776.7 million global cases of COVID-19 linked to SARS-CoV-2.¹ In Dominican Republic (DR) there have been approximately 661,103 cases and 4,384 deaths.¹
- While COVID-19 is now considered endemic in Latin America and the Caribbean (LAC),² both the region and DR experienced significant public health and economic burden from the COVID-19 pandemic,²⁻⁴ accounting

RESULTS (continued)

- In addition to outpatient costs, Table 1., and Figures 1 and 2 present the hospitalization costs (per-patient) both in the GW and UCI setting. In the GW the average cost (all age groups) in the high-risk patients was US\$2,450.2 for the unvaccinated and US\$2,425.9 for vaccinated patients (with higher costs for those over 50 years old), in contrast with In with US\$1938.4 (unvaccinated) and US\$1937.0 (vaccinated) in the low-risk group. In the ICU, the costs increased drastically, being on average US\$14,406.5 and US\$14,366.3 for high-risk; while low risk was US\$14,137.7 regardless of the vaccination status (Table 1.).
- The main cost drivers that influenced the total cost of ICU and GW were medications, laboratory tests and doctor/HCP visits (except for high-risk patients >50 years in GW,

for 25% of global cases and over 43% of deaths worldwide.⁵ Despite substantial efforts to mitigate the pandemic's impact in DR,^{4,6} from March 2020 to February 2022, adults aged 20-64 were primarily affected.⁷ However, individuals >50 years old faced the highest risk of fatal outcomes, with lethality rates increasing with age.⁷

COVID-19 remains a challenge to DR's Healthcare System (6,913 cases reported in epidemiological weeks 1-42 during 2024).⁸ However, the economic burden of this disease in adults remains poorly understood in the current context. To our knowledge, this is the first attempt to assess the economic impact of acute COVID-19 in DR during the endemic period.

OBJECTIVE

• Estimate the direct medical costs per patient related to the acute management of adult patients with COVID-19, from the perspective of DR's National Healthcare System (NHS).

METHODS

• A mixed structured approach was employed to identify, measure, and value resource use in estimating the cost of care for patients experiencing acute COVID-19 episodes. This encompassed a literature review, consultation and validation with clinical experts, as well as and resource evaluation using a where the hospitalization costs were twice than those of doctor/HCP visits). For instance, among high-risk groups (all ages), the average medication expenses in GW accounted for 55% (US\$1,338.54) and 48% (US\$922.79) of the total average cost per patient for unvaccinated and vaccinated individuals, respectively.

• Use of mechanical ventilation (MV) in the ICU increases costs by US\$14,846.8 for any age group and extends the LOS by 7-10 days.


Table 1. Overview of individual costs associated with the acute treatment of adults with COVID-19, categorized by treatment setting, age group, risk, and vaccination status.

Parameters		Outpatient Care (US \$) Low Risk – Unvaccinated patients	Hospital Care		
			GW (US \$)	ICU without MV (US \$)	
			Low Risk – Unvaccinated patients		
Age Group (years)	18 – 29	\$ 1,495.91	\$ 1,936.27	\$14,111.38	
	30-49	\$ 1,499.88	\$1,937.44	\$14,142.54	
	50-64	\$ 1,553.49	\$ 1,938.61	\$14,144.88	
	65-74	\$ 1,575.91	\$ 1,939.77	\$14,144.88	
	> 75	\$ 1,553.49	\$ 1,939.77	\$14,144.88	
		Low Risk – Ever vaccinated patients	Low Risk – Ever	Low Risk – Ever vaccinated patients	
Age Group (years)	18 – 29	\$ 1,438.66	\$ 1,934.86	\$14,141.37	
	30-49	\$ 1,441.46	\$1,936.03	\$14,142.54	
	50-64	\$1,495.08	\$1,937.20	\$ 14,144.88	
	65-74	\$ 1,517.49	\$ 1,938.36	\$14,144.88	
	> 75	\$ 1,495.08	\$ 1,938.36	\$ 14,144.88	
High Risk – Unvaccinated patients		High Risk – Unvaccinated patients	High Risk – Unvaccinated patients		
Age Group (years)	18 – 29	\$ 1,642.13	\$ 1,956.43	\$14,565.00	
	30-49	\$ 1,643.30	\$ 1,957.60	\$14,365.16	
	50-64	\$ 1,644.47	\$ 2,778.23	\$14,367.49	
	65-74	\$ 1,645.64	\$ 2,779.40	\$14,367.49	
	> 75	\$ 1,645.64	\$ 2,779.40	\$14,367.49	
High Risk – Ever vaccinated patients			High Risk – Ever vaccinated patients		
		• • • • • • •			

bottom-up micro-costing technique.

- A literature review was conducted to identify local clinical practice guidelines for adult patients (>18 years) in DR, as well as pertinent literature on the clinical management of the disease. This aimed to establish the use of required resources and identify cost-generating elements associated with the diagnosis, treatment, and management of COVID-19 across different settings: outpatient care, general ward hospitalization, and intensive care unit (ICU).
- A standardized questionnaire was administered to DR clinical experts to estimate the healthcare resource utilization (HCRU) for adult patients with COVID-19. The questionnaire also considered and validated factors like age group, vaccination status, and risk of severe outcomes (e.g., progression to severe COVID-19).
- A case-type methodology determined resource requirements for outpatient, general ward, and ICU settings which served to establish the base case. Unit costs were allocated to these resources using the National Health Service,⁹ Health and Labor Risks Superintendence,¹⁰ public tariffs for health services,¹¹⁻ ¹³ and the program of essential medicines.¹⁴ Costs in local currency were expressed in 2023 USD.

\$ 1,932.02 18 – 29 \$14,363.99 \$1,569.12 \$ 1,933.19 30-49 \$ 1,570.28 \$14,365.16 Age Group 50-64 \$ 1,571.45 \$ 2,753.82 \$ 14,367.49 (years) 65-74 \$ 1,572.62 \$ 2,754.99 \$14,367.49 > 75 \$ 1,572.62 \$ 2,754.99 \$ 14,367.49 MV= mechanical ventilation; US\$= United States dollar Color Key: ≥\$1,500-\$1,800 \$1,900 - \$2,500 \$1000-<\$1,500 \$2,600-\$3,000 ≥\$14,000



CONCLUSIONS

RESULTS

- For vaccination status, we presumed that **70%** of the adult population in DR had received at least one dose of a COVID-19 vaccine (i.e., "ever
- Higher costs were observed in patients over 50 years of age in GW (i.e., an age group more likely to die from COVID-19 than younger adults and children),¹⁸ compared to younger patients.
- Compared to vaccinated patients, unvaccinated high-risk patients used more health resources and incurred in higher expenses. Additionally, high-risk patients across all age groups had higher HCRU than low-risk patients.

Fig.1. Average cost per patient (all age groups) low risk group \$16,000 \$14,137.71 \$14,143.71 \$14,000 \$12,000 \$10,000 \$8,000 \$6,000 \$1,477.55 \$4,000 \$1,535.74 \$1,938.37 \$1,936.96 \$2,000 Low-Risk - Unvaccinated Low-Risk - Ever vaccinated Outpatient General Ward ICU (without MV)

vaccinated").^{15,16} Additionally, according to literature and clinical experts, about 60% of the adult population in DR has at least one comorbidity, such as hypertension, which is used as a risk factor of developing severe COVID-19/complications.^{16,17}

• The average cost of outpatient care (across all age groups) was **US\$1,644.2** and **US\$1571.2** in high-risk patients (10% of high-risk symptomatic patients required outpatient care), and US\$1,525.7 and US\$1477.5 in low-risk patients (95% of low-risk symptomatic patients required outpatient care), for unvaccinated and vaccinated patients, respectively (See Table 1., and Figures 1 and 2.)

• In high-risk groups, regardless of vaccination status, the length of stay (LOS) for adult symptomatic patients needing hospitalization was 5 days in general ward (GW) for patients under 49 years old and extended to 10 days for patients aged 65 and older. In the intensive care unit, the LOS was 10-15 days for all age groups.

The LAC region faced a substantial COVID-19 impact during the pandemic (especially in its initial phases), and despite COVID-19 has become endemic, it continues to circulate in LAC.² This study suggests that COVID-19 among adults still imposes considerable economic costs on DR's NHS. This underscores the importance of continuous preventive measures, such as vaccination, to mitigate the burden (particularly severe disease) and avert future infections and hospitalizations.

References 1. WHO. WHO COVID-19 dashboard. Accessed October 25, 2024, https://data.who.int/dashboards/covid19/cases?m49=001 2. Post LA, Wu SA, Soetikno AG, et al. Updated Surveillance Metrics and History of the COVID-19 Pandemic (2020-2023) in Latin America and the Caribbean: Longitudinal Trend Analysis. JMIR Public Health and Surveillance. 2024;10:e44398. 3. OECD, The-World-Bank. Health at a Glance: Latin America and the Caribbean 2023, 2023 [cited 2024 Oct 25]. Available from: https://www.oecd-ilibrary.org/content/publication/532b0e2d-en 4. Miranda J, et al. Central America and the Dominican Republic at Crossroads: The Importance of Regional Cooperation and Health Economic Research to Address Current Health Challenges. Value in Health Regional Issues. 2024;39:107–14. 5. PAHO. Q&A: SARS-CoV-2 in Latin America and the Caribbean 4 years later Washington, DC,2024 [cited 2024 Oct 25]. Available from: https://www.paho.org/en/news/23-2-2024-qa-sars-cov-2-latin-america-and-caribbean-4-years-later. 6. Finch E, et al. Effects of mobility, immunity and vaccination on SARS-CoV-2 transmission in the Dominican Republic: a modelling study. The Lancet Regional Health - Americas. 2024;37:100860 7. ONE. Boletín Demográfico y Social. 2022 - ISSN 2737-6796. Accessed October 25, 2024. Available from: boletín-demográfico-y-social-covid-2022-no-5.pdf 8. Dirección de Epidemiología, SINAVE. Boletín Epidemiológico Semanal. Semana 42. 13 de octubre hasta el 19 de octubre de 2024. Accessed October 25, 2024. Available from: https://epidemiologia.gob-do . 9. Servicio Nacional de Salud. Reporte de revisión de expedientes clínicos de pacientes COVID-19 ingresados en hospitales públicos de la Republica Dominicana. [Internet]. Servicio Nacional de Salud; 2020. (Periodo Marzo – junio 2020.). Available from: 10. Superintendencia de Salud y Riesgos Laborales. Resolución Administrativa Arbitral DJ-CA No. 0002-2023 [Internet]. República Dominicana; 2023. 11. Seguro Nacional de Salud (SeNaSa). Tarifario Regimen Subsidiadio (PBS-1.0) [Internet]. [cited 2024 Apr 30]. Available from: Sociedad Dominicana de Urología. Tarifario ARS Monumental 2020 [cited 2024 Apr 30]. [Internet]. 12. 13. Servicio Nacional de Salud. Inventario medicamentos Trimestre Enero-Marzo 2019 [Internet]. 2019 [cited 2024 Apr 30]. Available from: 14. Gobierno de la República Dominicana. Portal Nacional de Datos Abiertos de la República Dominicana. 2021 [cited 2024 Apr 30]. Lista de medicamentos y precios en las Farmacia del Pueblo, 2022 - Datos abiertos. Available from: https://datos.gob.do/dataset/listado-de-precios-en-las-farmacias-del-pueblo-promese-cal 15. Oficina Nacional de Estadística (ONE). Boletin Demografico y Social 2022 [Internet]. República Dominicana: Oficina Nacional de Estadística; 2022 mar [cited 2024 Apr 18]. Report No.: N°5. Available from: https://www.one.gob.do/media/b0afxkbk/bolet%C3%ADn-demogr%C3%A1fico-y-social-covid-2022-no-5.pdf 16. Consulta Expertos Clínicos de República Dominicana. 2024. 17. Colón F, Sebelén E, García N, et al. Factores asociados a severidad y mortalidad en pacientes con COVID-19: estudio multicéntrico en República Dominicana. CYSA. 2023 7(2):17-30. 18. COVID-19 National Preparedness Collaborators. Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021. Lancet. 2022;399(10334):1489-1512.

Acknowledgments: Graphic design and editorial support were provided by Eliana Vasquez of NeuroEconomix and was funded by Pfizer.

Disclosures: This study was funded by Pfizer Inc. JJBC, LAB, AV, MML, are employees of Pfizer CAC. CFM,MO are employees of Pfizer Inc. PL, MO is a Morgan State University Doctoral Fellow. VE are employees of NeuroEconomix, which was contracted by Pfizer to conduct this study.



For more information please contact: Juan José Baldi Castro Pfizer Inc. Email: juanjose.baldi@pfizer.com



Abstract ID 143307. Presented at the ISPOR Europe Conference, 17–20 November 2024, Barcelona, Spain